- Home
- LWAY vs CNTX Comparison
LWAY vs CNTX Comparison
Compare LWAY & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LWAY | CNTX |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.3M | 283.9M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LWAY | CNTX |
|---|---|---|
| Price | $18.30 | $2.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $35.00 | $6.60 |
| AVG Volume (30 Days) | 46.1K | ★ 937.4K |
| Earning Date | 03-17-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.33 | 17.39 |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $103,350,000.00 | N/A |
| Revenue This Year | $15.20 | N/A |
| Revenue Next Year | $16.67 | N/A |
| P/E Ratio | $20.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.31 | $0.49 |
| 52 Week High | $34.20 | $3.62 |
Technical Indicators
Market Signals| Indicator | LWAY | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 33.21 | 47.55 |
| Support Level | $17.31 | $2.07 |
| Resistance Level | $22.80 | $2.72 |
| Average True Range (ATR) | 0.86 | 0.29 |
| MACD | -0.13 | -0.08 |
| Stochastic Oscillator | 23.21 | 11.50 |
Price Performance
Historical ComparisonAbout LWAY Lifeway Foods Inc.
Lifeway Foods Inc is engaged in manufacturing probiotic, cultured, functional dairy health food products. Its primary product is drinkable kefir which is a cultured dairy product. Its product categories are Drinkable Kefir which is the key revenue-driving product, European-style soft cheeses, Cream, ProBugs, Frozen Kefir and Other dairy. The company manufacture and market products under the Lifeway and Fresh Made brand names, as well as under private labels on behalf of customers. It sells the products through direct sales force, brokers, and distributors.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.